Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

274results about How to "Prevent elution" patented technology

Drug-eluting stent for controlled drug delivery

The present invention provides a stent for delivering drugs to a vessel in a body, including a stent framework with a plurality of micropore reservoirs formed therein using a femtosecond laser, a drug polymer positioned in the reservoirs, and a polymer layer positioned on the drug polymer. The present invention also provides a method of manufacturing a drug-polymer stent and a method of treating a vascular condition using the drug-polymer stent.
Owner:MEDTRONIC VASCULAR INC

Electrolyte solution for secondary battery and secondary battery using the same

The present invention provides a technology of inhibiting the decomposition of the solvent of the electrolyte solution for the secondary battery. Further, the present invention provides a technology of prohibiting the resistance increase of the secondary battery and improving the storage properties such as improving the capacity retention ratio. The electrolyte solution 15 comprising non-proton solvent and cyclic sulfonic ester including at least two sulfonyl groups may be used.
Owner:NEC CORP

Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.
Owner:WYETH LLC

Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and / or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and / or compounds from the implantable medical devices.
Owner:WYETH LLC

Pulse charge method for nonaqueous electrolyte secondary battery and pulse charge control device

A pulse charge method for a nonaqueous electrolyte secondary battery, includes: a charge control step of pulse charging by supplying a pulsed current periodically to the nonaqueous electrolyte secondary battery; a battery voltage detection step of measuring a battery voltage of the nonaqueous electrolyte secondary battery; a comparison step of comparing the battery voltage, measured in the battery voltage detection step when the pulsed current is supplied, with a predetermined set voltage; and a charge end control step of ending the pulse charging when a comparison result shows that the measured battery voltage is equal to or higher than the set voltage.
Owner:PANASONIC CORP

Non-aqueous electrolyte and non-aqueous electrolyte secondary battery using the same

A non-aqueous electrolyte can suppress decomposition of a solvent, improve the cycle life of a secondary battery, suppress the rise of resistance of a secondary battery and improve the capacity maintenance ratio of a secondary battery A non-aqueous electrolyte secondary battery formed by using such a non-aqueous electrolyte includes a non-aqueous electrolyte containing an aprotic solvent and a disulfonic acid ester as expressed by chemical formula 1 shown below, a positive electrode and a negative electrode:
Owner:NEC ENERGY DEVICES LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products